Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Plan B Public Debate May Spotlight Smoking Cessation Age Limit Precedent

This article was originally published in The Tan Sheet

Executive Summary

FDA's age-based approval for OTC sale of smoking-cessation drugs sets a precedent that addresses the agency's concerns about age-related marketing of Barr Labs' emergency contraceptive Plan B, according to NCI Consulting President Sue Coleman

You may also be interested in...



Increased Plan B Access Just One Factor In Abortion Reduction – Wood

A "huge gulf" exists "between making emergency contraception available over the counter and actually seeing a reduction in nationwide abortion rates," NEJM Editor Jeffrey Drazen and FDA Nonprescription Drugs Advisory Committee Chair Alastair Wood contend

Increased Plan B Access Just One Factor In Abortion Reduction – Wood

A "huge gulf" exists "between making emergency contraception available over the counter and actually seeing a reduction in nationwide abortion rates," NEJM Editor Jeffrey Drazen and FDA Nonprescription Drugs Advisory Committee Chair Alastair Wood contend

Increased Plan B Access Just One Factor In Abortion Reduction – Wood

A "huge gulf" exists "between making emergency contraception available over the counter and actually seeing a reduction in nationwide abortion rates," NEJM Editor Jeffrey Drazen and FDA Nonprescription Drugs Advisory Committee Chair Alastair Wood contend

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098608

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel